BioSpace News Archive

The beginning of virtual clinical trials is going to be a game-changer. Why they are going to be game-changer? What changes will occur? Know it all here.

One of the big topics presented at the Alzheimer’s Association International Conference (AAIC) 2019 in Los Angeles was the effect of lifestyle on the risk of Alzheimer’s disease.

Gilead Sciences, Inc. and Galapagos NV announced that they have entered into a 10-year global research and development collaboration.

Ascentage Pharma announced that the company recently dosed the first patient successfully in a Phase I clinical trial of APG-2575, a novel Bcl-2 selective inhibitor, for the treatment of hematologic malignancies in China.

AirXpanders, Inc. announced that the company has received U.S. Food and Drug Administration 510 clearance to market a smooth shell version of the AeroForm Tissue Expander.

New research reported at the Alzheimer’s Association International Conference (AAIC) 2019 in Los Angeles suggests healthy lifestyle choices — including healthy diet, exercise, and cognitive stimulation — may decrease risk of cognitive decline and dementia.

New studies reported at the Alzheimer’s Association International Conference (AAIC) 2019 in Los Angeles demonstrated the utility of technology to address Alzheimer’s disease and other dementias from three different angles — direct care of people living with the disease, assistance for caregivers, and prevention education for young people.

RaySearch and Vision RT, two of the leading companies in the radiation oncology space, today announced a strategic partnership, to work together on technology development projects

Two studies reported at the Alzheimer’s Association International Conference (AAIC) 2019 in Los Angeles found that experiencing multiple sensory impairments, such as vision and hearing problems, are associated with an increased risk of developing dementia in older adults.

New research reported at the Alzheimer’s Association International Conference (AAIC) 2019 in Los Angeles found higher rates of subjective cognitive decline among lesbian, gay, bisexual and/or transgender (LGBT) Americans compared to their cisgender* heterosexual counterparts.